China Universal CSI Chinese Medicine ETF(560080) rises 2.58%, aiming for a fifth consecutive gain

NewTimeSpace (newtimespace.com) News, as of 13:44 on July 16, 2026, China Universal Traditional Chinese Medicine ETF (560080) rose 2.58%, aiming for a fifth consecutive gain. The latest price was 1.03 yuan. Over a longer time frame, as of July 15, 2026, the ETF accumulated a gain of 9.57% over the past week, ranking 2/4 among comparable funds.

In terms of liquidity, China Universal Traditional Chinese Medicine ETF recorded an intraday turnover rate of 4.72% and a trading volume of 128 million yuan. Over a longer time frame, as of July 15, the ETF's average daily trading volume over the past week reached 142 million yuan, ranking first among comparable funds.

In terms of scale, the latest scale of China Universal Traditional Chinese Medicine ETF reached 2.697 billion yuan, hitting a six-month high and ranking 1/4 among comparable funds. (Data source: Wind)

In terms of shares, China Universal Traditional Chinese Medicine ETF experienced a significant increase of 36.00 million units in share count over the past week, with the new share increase ranking 1/4 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net outflow from China Universal Traditional Chinese Medicine ETF was 16.0029 million yuan. Over a longer time frame, within the past five trading days, it attracted a total of 29.3577 million yuan in net inflow. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of China Universal Traditional Chinese Medicine ETF reached 8.7274 million yuan, with the latest margin financing balance standing at 51.2558 million yuan. (Data source: Wind)

From the perspective of return capability, as of July 15, 2026, since its inception, China Universal Traditional Chinese Medicine ETF achieved a highest single-month return of 16.46%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 20.20%, and an average return of 4.95% in up months. As of July 15, 2026, the ETF's annualized excess return over its benchmark for the past three months was 7.19%, ranking in the top 2/4 among comparable funds.

In terms of drawdown, as of July 15, 2026, China Universal Traditional Chinese Medicine ETF recorded a drawdown of 0.07% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.

In terms of fees, China Universal Traditional Chinese Medicine ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of July 15, 2026, the three-year tracking error of China Universal Traditional Chinese Medicine ETF was 0.043%, achieving the highest tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Traditional Chinese Medicine Index, which China Universal Traditional Chinese Medicine ETF tracks, is only 21.93 times, standing at the 16.67% percentile over the past year. This means the valuation is lower than over 83.33% of the time in the past year, placing it at a historical low.

China Universal Traditional Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index. The CSI Traditional Chinese Medicine Index selects the securities of listed companies whose businesses involve the production and sale of traditional Chinese medicine as index constituents, in order to reflect the overall performance of traditional Chinese medicine concept listed companies.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.